# Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

> **NCT01464905** · PHASE3 · UNKNOWN · sponsor: **Nuron Biotech Inc.** · enrollment: 500 (estimated)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** NU100
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** rhIFN beta-1b

## Key facts

- **NCT ID:** NCT01464905
- **Lead sponsor:** Nuron Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-10
- **Primary completion:** 2013-12
- **Final completion:** 2014-12
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2013-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01464905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01464905, "Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01464905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*